Enfusion (NYSE:ENFN) Reaches New 12-Month High – What’s Next?

Enfusion, Inc. (NYSE:ENFN) shares reached a new 52-week high on Monday . The stock traded as high as $10.41 and last traded at $10.35, with a volume of 166401 shares traded. The stock had previously closed at $10.21.

Enfusion Trading Up 0.9 %

The stock has a fifty day moving average of $9.43 and a 200-day moving average of $8.93. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 264.00, a PEG ratio of 3.82 and a beta of 0.97.

Insiders Place Their Bets

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 36.44% of the company’s stock.

Institutional Trading of Enfusion

Large investors have recently made changes to their positions in the stock. RiverPark Advisors LLC acquired a new position in Enfusion during the 2nd quarter valued at $68,000. Arizona State Retirement System acquired a new position in shares of Enfusion during the second quarter valued at about $86,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Enfusion in the first quarter valued at about $102,000. Harbor Capital Advisors Inc. grew its position in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares in the last quarter. Finally, Belvedere Trading LLC acquired a new position in Enfusion in the 3rd quarter valued at approximately $114,000. Institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.